Analysts Offer Predictions for Precigen FY2025 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Investment analysts at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for Precigen in a report issued on Thursday, May 15th. Cantor Fitzgerald analyst J. Kim now forecasts that the biotechnology company will post earnings per share of ($0.37) for the year, down from their prior forecast of ($0.27). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share.

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Precigen in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Precigen presently has a consensus rating of “Moderate Buy” and an average target price of $7.00.

Precigen Price Performance

PGEN stock opened at $1.41 on Monday. The company has a 50 day moving average price of $1.48 and a 200 day moving average price of $1.31. Precigen has a fifty-two week low of $0.65 and a fifty-two week high of $2.17. The stock has a market capitalization of $416.18 million, a PE ratio of -2.56 and a beta of 1.82.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. The firm had revenue of $1.34 million during the quarter, compared to analysts’ expectations of $0.50 million. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%.

Institutional Trading of Precigen

Institutional investors have recently bought and sold shares of the business. LexAurum Advisors LLC grew its holdings in Precigen by 151.9% during the 4th quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock worth $775,000 after acquiring an additional 417,055 shares during the period. Iridian Asset Management LLC CT grew its holdings in Precigen by 38.8% during the 4th quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company’s stock worth $5,871,000 after acquiring an additional 1,465,962 shares during the period. Barclays PLC grew its holdings in Precigen by 190.4% during the 3rd quarter. Barclays PLC now owns 189,353 shares of the biotechnology company’s stock worth $179,000 after acquiring an additional 124,141 shares during the period. Rhumbline Advisers grew its holdings in Precigen by 7.3% during the 4th quarter. Rhumbline Advisers now owns 197,134 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 13,338 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Precigen by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 3,299,851 shares of the biotechnology company’s stock worth $3,696,000 after acquiring an additional 53,343 shares during the period. Institutional investors and hedge funds own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.